Laura Bello-Corral1
Leticia Sánchez-Valdeón1*Inés Casado-Verdejo1Jesús Ángel Seco-Calvo2,3
Jesús Antonio Fernández-Fernández1María Nélida Fernández-Martínez4- 1Department of Nursing and Physical Therapy, University of León, León, Spain
- 2Institute of Biomedicine, University of León, León, Spain
- 3University of the Basque Country, Leioa, Spain
- 4Department of Biomedical Sciences, IBIOMED, University of León, León, Spain
Alzheimer's disease (AD) is a primary, progressive, neurodegenerative disorder. Many risk factors for the development of AD have been investigated, including nutrition. Although it has been proven that nutrition plays a role in AD, the precise mechanisms through which nutrition exerts its influence remain undefined. The object of this study is to address this issue by elucidating some of the mechanisms through which nutrition interacts with AD. This work is a qualitative systematic bibliographic review of the current literature searchable on various available databases, including PubMed, Web of Science, and Google Scholar. Our evidence comprises 31 articles selected after a systematic search process. Patients suffering with AD present a characteristic microbiome that promotes changes in microglia generating a proinflammatory state. Many similarities exist between AD and prion diseases, both in terms of symptoms and in the molecular mechanisms of pathogenesis. Changes in the composition of the gut microbiome due to dietary habits could be one of the environmental factors affecting the development of AD; however, this is probably not the only factor. Similarly, the mechanism for self-propagation of beta-amyloid seen in AD is similar to that seen in prions.
Introduction
Alzheimer's disease (AD) is a primary neurogenerative disease characterized by subtle initial symptoms, such as alterations in memory that worsen incrementally. Symptoms progress to include behavioral changes and, in the final stages of the disease, the patient becomes wholly dependent (Mosconi and McHugh, 2015). This disease represents ~ 50–75% of all dementia cases, making it the most common form of dementia (Pistollato et al., 2016; Europe, 2017).
The pathology of AD is defined by the presence of extracellular senile plaques and intracellular neurofibrillary tangles formed, respectively, by beta-amyloid peptides and tau-proteins (Bhardwaj et al., 2017). In addition to these two key neurological pathologies, other features of AD include synaptic loss, marked hippocampal and cortical gliosis, a prominent oxidative stress, and an accumulation of vascular amyloid plaques within the brain, all of which contribute to neurological deterioration (Perl, 2010). Cerebral atrophy and excessive neuroinflammation are additional aspects of the disease (Association, 2018).
Although the origin of AD is still unknown, genetic and environmental factors that affect the evolution of the disease are known (Fern and Ruiz-Gabarre, 2019), such as different eating patterns, among others (Joseph et al., 2009; Abate et al., 2017).
At present, it remains an incurable disease, although there are pharmacological treatments, but with a limited therapeutic range (Mosconi and McHugh, 2015). However, there are studies that explore new therapies that could slow the progression of AD. Examples of these are cell therapy, based on the use of pluripotent stem cells from mature somatic cells, which may be a possible route in the treatment of AD (Guarnieri et al., 2018). A neuroprotective effect of estrogens against the inflammatory response produced by cholinergic neurons has also been observed in AD (Sarchielli et al., 2020). Neurons affected in AD show significant dysfunction in mitochondria and in the mitophagy process. For this reason, various therapeutic routes directed at mitophagy are being carried out in preclinical studies, since they can have wide applications due to their vital role in the initiation and progression of various neurodegenerative diseases (Rai et al., 2020).
As mentioned above, there are different eating patterns. Thus, increasing the intake of fruits, vegetables and fish in the diet has been shown to be beneficial for brain health (Moore et al., 2018). Nutrition influences cognitive and neurobiological changes in older adults, while a healthy diet seems to tip the balance in favor of a healthier senescence and seems to reduce the neurodegenerative risk in pathologies such as AD and other dementia entities (Gardener and Rainey-Smith, 2018). That is why nutrition and dietary patterns are key factors in the clinical care of people with cognitive impairment, because some vitamins, minerals and micronutrients have important antioxidant, anti-inflammatory and free radical scavenging properties that can protect oxidative damage, neuroinflammation and subsequent cognitive impairment (Dominguez and Barbagallo, 2016).
On the other hand, it is also related to nutrition, the constant risk of weight loss and a worsening of the nutritional status that patients with AD present as the disease progresses (Vieira et al., 2014). In AD, there is damage to areas of the cerebral cortex involved in the control of intake, also producing an impairment in serotonergic, dopaminergic and adrenergic neurotransmission. These neurotransmitters are essential in the regulation of eating behavior, which is why there is a progressive loss of appetite and finally a suspension of intake, which leads to a significant decrease in nutritional intake (Cardoso et al., 2013). Weight loss and malnutrition can contribute to the increase and progression of cognitive decline, loss of independence for daily activities, institutionalization, and increased mortality (Vieira et al., 2014).
Among the most notable dietary patterns is the Mediterranean diet, characterized by a high intake of vegetables, fruits, legumes, fish, cereals, and unsaturated fat, mainly olive oil. The Mediterranean diet has been found to be beneficial in reducing neurodegenerative risks. There is a combination between the Mediterranean diet and the diet focused on curbing Hypertension (DASH), this union produces what we call the Intervention Diet for Neurodegenerative Delay (MIND), which has a neuroprotective effect (Gardener and Rainey-Smith, 2018; Brink Van Den et al., 2019). This diet is characterized by the consumption of natural foods of vegetable origin, specifically the increase in green leafy vegetables, and a decrease in the consumption of foods of animal origin and with a high content of saturated fat (Gardener and Rainey-Smith, 2018; Brink Van Den et al., 2019).
However, the precise nature of how these diets act on cerebral physiology remains to be determined, although it is postulated to be due to growth in neurite extension and synaptogenesis (Gardener and Rainey-Smith, 2018).
Two theories can shed light on the mechanisms by which nutrition is involved, namely: the human microbiome as an important contributing factor to nutritional status, health, and disease (Bhattacharjee and Lukiw, 2013); and the appearance of prion disorders as a result of dietary exposure (Da et al., 2011).
The Inflammatory Theory of the Microbiota
There are various factors that affect the acquisition and maturation of the microbiota, some of them are the type of delivery (cesarean or vaginal), antibiotics, breastfeeding, diet or environmental exposure to microbes (Cox and Weiner, 2018). Diet is recognized as one of the factors with the most influence on the intestinal microbiota. There is evidence that nutritional patterns with high or low amounts of fiber and diets based on plants or animals rapidly and reproducibly modify the intestinal microbial composition (Heiss and Olofsson, 2018).
Recent studies have shown that certain pathologies such as inflammatory bowel disease, irritable bowel syndrome, gastrointestinal infections, allergic diseases, diabetes and metabolic syndrome are related to an altered microbiota and are associated with the state mood, behavior, and cognition (Agahi et al., 2018; Giau et al., 2018). At present, the gut microbiota is of great interest in relation to various neurodegenerative diseases (Leblhuber et al., 2018), including AD (Rosa et al., 2018) as well as prion diseases (D'Argenio and Sarnataro, 2019). It has been observed that both, the production of beta-amyloid peptide in AD and neuroinflammation have been related to the intestinal microbiota, also microbiome has been described to have a role in the activation of the microglia in prion diseases (D'Argenio and Sarnataro, 2019).
Neuroinflammation and oxidative stress are factors that have been affected by the intestinal microbiota (Agahi et al., 2018). The gut microbiota and the central nervous system (CNS) are connected through multiple bidirectional pathways involving neuronal, endocrine, and immune signaling (Cox and Weiner, 2018).
Recent studies indicate that the human microbiota could contribute to the regulation of various neurochemical and neurometabolic pathways through a series of complex networks involving the microbe-ta-host symbiosis that systematically connect the gastrointestinal system, skin, liver and other organs with the CNS (Bhattacharjee and Lukiw, 2013).
Prion Theory
Prion proteins exist both in normal cellular form and in an infectious, abnormally folded form. Upon coming into contact with the normal isoform, malformed prions cause these to misfold, which produces a cascade effect leading to cellular death (Abbott, 2016). Thus, there exist a cellular prion protein (PrPC), a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on the surface of cells and expressed in mammalian tissues, primarily in the CNS, and, in addition, its conformationally modified isoform, termed “Scrapie” (PrPSc), which is the principal component of prions (Toni et al., 2017).
Prions are an aetiological agent for a rare set of neurodegenerative disorders known as transmissible spongiform encephalopathies (TSEs) or prion diseases (Toni et al., 2017). The pathophysiology and pathogenesis of these diseases is characterized by marked brain spongiform change due to vacuolation, neuronal loss, astrocytosis, and intracerebral accumulation of folded prion protein (Walker and Jucker, 2015).
Several experimental transmission routes have been investigated for prion disorders such as intra-ocular, intraventricular, intraperitoneal, intraspinal and subcutaneous injections, however, most prion diseases are contracted by ingestion of PrPSc (Da et al., 2011).
It has been shown that the intestine has a key role in the transmission of prion proteins (Walker and Jucker, 2015). One of the pathways by which PrPSc gains access the intestine involves the endocytic membranous cells, which aid the translocation of these proteins from the intestinal epithelium into the lymphoid tissues. From here, prions can pass into the follicular dendritic cells, allowing their transport to the mesenteric lymphatic ganglions. In this way, the prion proteins can reach the enteric nervous system (ENS) and ultimately enter the CNS (Da et al., 2011).
It has been observed that, after oral administration, prions can resist the digestion process and enter the intestinal epithelium, where they interact with dendritic cells or macrophages, being able to accumulate in follicular dendritic cells and from there move to the ENS (Heiss and Olofsson, 2018). Enterocytes are the main cell population of the intestinal epithelium due to their ability to endocyte pathogens, nutrients, and macromolecules. It has been proposed that these cells could be a prominent entry site for food prions (Da et al., 2011).
Recently, it was suggested that amyloidogenic proteins, characteristic of the pathology of AD, are able to self-replicate in a similar manner to prions (Ashe et al., 2013). It should be noted that the neuropathology of Creutzfeldt – Jacob disease (CJD) shows similarities with AD, since both show neuronal damage, mitochondrial abnormalities, and oxidative damage, and both show inflammatory changes led by brain microglial proliferation. The main difference is the evolution of the disease, which progresses more rapidly in CJD than AD (Bastian, 2017).
Objective
There is multiple evidence that could suggest that nutrition is closely related to AD, but the state of the art is still unclear; thus, the objective of this work is to shed light on the mechanisms by which nutrition is linked to AD through a systematic literature review. These mechanisms may be related to either of two theories: the prion theory or the microbiota inflammation theory.
Materials and Methods
This work constitutes a qualitative systematic bibliographic review. The strategy employed for the literature search is summarized in Figure 1 and involved the use of several scientific databases, including Web of Science, Google Scholar and PubMed. The aim was to find answers to the questions posed in our objectives. Other sources of information were the publication catalogs in public libraries and various guides held by foundations; associations; and public and private institutions related to the themes addressed in the objectives of this work.
Figure 1. Flow diagram.
The methodology for our search strategy involved the use of certain key words, namely Alzheimer's disease, nutrition, neuroinflammation, gut microbiome, amyloid prion, transmissible prion.
The search was limited using filters to select articles in English published between 2009 and 2020 that focused on the themes pertinent to this study with the aim of uncovering evidence about the mechanisms through which nutrition is linked to AD.
After first reading all abstracts, we excluded those articles that did not contain material related to the theme of this work, that is, investigations into other sorts of dementia and those linking AD to forms of care other than nutritional.
In addition, through a “snowball effect” search of the literature reviews contained in the articles we consulted, we found other studies. Many of these are included here because they bring together some of the objectives set out in the present work.
Results
The literature search yielded a total of 588 articles from the various databases and other information sources consulted. Of these, 244 were selected for full review and 31 were then chosen to form part of the evidence used in this work. Subsequently, the focus was on whether articles looked at the relationship between AD and nutrition as either mediated through the microbiota theory or the prion theory.
A total of 31 studies were selected, of which 11 are preclinical, carried out in mice with different age ranges (Morales et al., 2010; Stöhr et al., 2012; Pietri et al., 2013; Noh et al., 2014; Wu et al., 2014; Minter et al., 2016; Harach et al., 2017; Bonfili et al., 2018; Khan et al., 2018; Purro et al., 2018; Zhao et al., 2019) and other types of clinical investigations that included four cross-sectional studies (Claesson et al., 2012; Fernández-Navarro et al., 2016; Cattaneo et al., 2017; Vogt et al., 2017), two randomized, double-blind, placebo-controlled clinical trial (Akbari et al., 2016; Agahi et al., 2018), two prospective observational studies (Pendyala et al., 2012; Morris et al., 2016), one longitudinal study (Anastasiou et al., 2017), four clinical cases were also evaluated (Haraguchi et al., 2009; Yoshida et al., 2010; Jaunmuktane et al., 2015; Aoyagi et al., 2019) and seven were added systematic bibliographic reviews (Li et al., 2016; Lukiw, 2016; Bastian, 2017; Mancuso and Santangelo, 2017; Singh et al., 2017; Zhan et al., 2018; Dohrmann et al., 2019).
Of the 31 articles selected as evidence, 21 are included in the first section which concerns the microbiota and its links to AD. The remaining 10 articles are in the second section which outlines the prion theory in relation to AD.
As shown in Table 1, the first section is introduced by two studies describing the characteristic type of microbiota found in patients suffering from AD (Harach et al., 2017; Vogt et al., 2017). Later, studies were classified according to the form of analysis used in relation to their study of microbiota and AD. One study included centers on neuroinflammation in AD patients and its possible relation to microbiota characteristics (Cattaneo et al., 2017); see Table 2. Other studies, summarized in Table 3, highlighted the role of lipopolysaccharides (LPS) in the immune systems of people with AD (Noh et al., 2014; Lukiw, 2016; Zhao et al., 2019). Also included were two studies, simplified explanations of which can be found in Table 4, that analyzed the levels of gamma-aminobutyric acid (GABA), a neurotransmitter which appears to be important in AD (Wu et al., 2014; Li et al., 2016). In addition, a further five studies, explained in Table 5, were included because they deal with possible therapeutic approaches to AD (Akbari et al., 2016; Minter et al., 2016; Agahi et al., 2018; Bonfili et al., 2018; Khan et al., 2018). At the end of this section, a total of eight investigations were grouped together, see Table 6, in which microbiota were related with diet (Claesson et al., 2012; Pendyala et al., 2012; Fernández-Navarro et al., 2016; Hu et al., 2016; Morris et al., 2016; Anastasiou et al., 2017; Singh et al., 2017; Dohrmann et al., 2019).
Table 1. Microbiota and Alzheimer's disease (AD).
Table 2. Microbiota and neuroinflammation.
Table 3. Microbiota and the immune system.
Table 4. Microbiota and gamma-aminobutyric acid (GABA).
Table 5. Microbiota and therapy in AD.
Table 6. Microbiota and diet in AD.
In the second section are a collection of studies, shown in Table 7, that evaluate the resemblances between the pathogenic protein implicated in prion diseases and the beta-amyloid peptides characteristic of AD pathology (Aguzzi, 2014), in addition to the similarities between CJD and AD (Bastian, 2017). Other studies shown in this table analyzed the interaction occurring when pathological proteins and the beta-amyloid peptides found with AD are co-present in the brain (Morales et al., 2010; Stöhr et al., 2012; Aoyagi et al., 2019). A further set of investigations involved studies of the autopsies of patients that had died of CJD where deposits of beta-amyloid peptides were found, indicating possible iatrogenic transmission (Haraguchi et al., 2009; Yoshida et al., 2010; Jaunmuktane et al., 2015; Purro et al., 2018). The final study in this section looks at the enzyme 3-Phosphoinositide-dependent protein kinase-1 (PDK1), both in AD and prion disease (Pietri et al., 2013).
Table 7. Prion theory.
Discussion
The results of our review suggest that AD has been associated with dietary factors, because an excessive intake of saturated fat, among others, influence the disease. These dietary factors can promote or prevent the degeneration of nerve cells.
Numerous studies around the world have shown a correlation between various dietary patterns and their incidence in AD, indicating that diet acts as a modifiable risk factor (Barnard et al., 2014; Venturini et al., 2014; Ravi et al., 2018).
In a bibliographic review in which ecological and observational studies from various countries were selected to determine nutritional risk factors and AD, it was concluded that the Western dietary pattern characterized by a high consumption of meat is strongly associated with risk of developing AD. Traditional diets in India, Japan and Nigeria, with a very low intake of meat, were found to be associated with a 50% reduction in the risk of developing AD. Furthermore, this literature review shows that maintaining vitamin D concentrations above 75 nmol/L could help reduce the risk of AD (Grant and Grant, 2016).
Microbiota and AD
One study observed that individuals with AD had less diversity and significant taxonomic differences in their gut microbiota compared to an age- and sex-matched control group. Similarly, their particular bacterial taxa were correlated with biomarkers for AD (Vogt et al., 2017). Findings showed that three specific bacterial genera were more abundant in subjects with AD and these correlated with the biomarkers for beta-amyloids and tau-protein (Vogt et al., 2017).
It was observed in another preclinical study that in the intestine of transgenic mice with AD there is a significant reduction in the bacteria that belong to the phyla Firmicutes and Actinobacteria and an increase in the number of Bacteroidetes and Tenericutes compared to the control group (Harach et al., 2017).
On the other hand, it has been shown that changes in the composition of the microbiota occur with age, which has an impact on protein function and function in the CNS (Amato et al., 2020).
Microbiota and Neuroinflammation
In a recent study of a clinical trial, subjects testing amyloid+ showed lower numbers of Eubacterium rectale bacteria and a greater abundance of Escherichia and Shigella bacteria in comparison to a control group (Cattaneo et al., 2017). In addition, it was observed that, compared to the control group, blood samples from amyloid+ patients showed increased levels of proinflammatory cytokines, interleukin 1 (IL-1) and IL-6, among others. Finally, a correlation was identified between increases in blood levels of proinflammatory cytokines and increases in numbers of the Escherichia and Shigella species of bacteria. The presence of the anti-inflammatory species, Eubacterium rectale, leads to an absence of proinflammatory cytokines (Cattaneo et al., 2017).
Recent studies have indicated that microbial dysbiosis can influence the formation of beta-amyloid fibrils, which could enhance neuroinflammatory activity in AD and the deposition of these beta-amyloid fibrils at brain level (D'Argenio and Sarnataro, 2019).
Microbiota and the Immune System
LPS are large molecules associated with certain pathogens which can activate an immune response in many types of cell, in particular those associated with the innate immune system. When activated these cells produce large quantities of proinflammatory cytokines, such as IL-6, IL-1α, and IL-1β, among others, which can cross the blood-brain barrier, reaching the brain via diffusion. Once inside the brain, cytokines act on the neuronal receptors and microglia, altering their activation state and physiology (Sampson et al., 2016).
Gram-negative bacteria are composed of an external membrane made of LPS, which constitutes their principal proinflammatory agent (Noh et al., 2014; Zhan et al., 2018). In rat studies, the administration of LPS resulted in neurotoxicity, microglial activation, and neuronal degeneration (Noh et al., 2014). Other authors have investigated the potential relationship between cognitive deterioration and neuroinflammation by administering LPS to mice (Noh et al., 2014). In these studies, LPS produced cognitive deterioration in the mice, accompanied by microglial activation and the loss of neurones from the hippocampus. Measurement of the levels of expression for several proinflammatory cytokines, such as tumor necrosis factor (TNF-α), IL-1β, prostaglandin E2 (PGE2), and nitric oxide (NO), revealed that levels of TNF-α and IL-1β were high compared to those measured for the control group. These findings demonstrate that LPS can provoke inflammation and the release of proinflammatory cytokines (Noh et al., 2014). The authors of this study presented these findings in a mouse model with neuronal inflammation and neurodegenerative pathology, as seen in AD (Noh et al., 2014).
Moreover, the authors of a review concluded that in the brain of patients with AD there is a significantly higher amount of LPS from large-negative batteries compared to the control group (Zhao et al., 2017).
However, a dual effect of TNF-α on the phenotypic plasticity of a model of cholinergic neuroblasts of the human basal forebrain has been studied, in which a negative effect on neurogenesis has been observed, but also a positive effect in differentiation, inducing phenotypic changes in neuroblasts still undifferentiated to a specific lineage (Guarnieri et al., 2020).
By comparison, LPS produced by the bacterium of the genus Bacteroides fragilis is recognized by microglia receptors in the same way as the proinflammatory 42 amino acid beta-amyloid peptide (Aβ42) associated with AD. This provides evidence that exposure of human brain cells to LPS from B. fragilis is a potent inducer of the proinflammatory transcription factor complex NF-Kb, a well-known trigger in the expression of the pathogenic pathways involved in neurodegenerative inflammation (Lukiw, 2016).
Microbiota and GABA
GABA is the principal inhibitory neurotransmitter found in the CNS of mammals (Li et al., 2016). Increased levels of GABA in the intestinal tract are correlated with raised levels of GABA in the CNS. Dysbiosis in the gut microbiota, particularly a reduction in numbers of Lactobacillus and Bifidobacterium, influences GABA production in the intestine and leads to a decrease in levels of this neurotransmitter in the CNS (Hu et al., 2016).
The first studies in the human brain post-mortem, and in animal models, concluded that both neurons and GABAergic receptors seem to be most resistant to AD pathology, showing only moderate losses with this disease (Li et al., 2016). Later post-mortem studies revealed a decrease in levels of this neurotransmitter within the frontal, temporal, and parietal cortices (Mancuso and Santangelo, 2017). Nevertheless, it has recently been shown that GABAergic neurotransmission undergoes severe pathological alterations in AD (Li et al., 2016). In fact, one study using an AD mouse model found high GABA levels in reactive astrocytes in the dentate gyrus. Reactive astrocytes are hypertrophic glial cells containing high levels of glial fibrillary acidic protein that are activated as a result of lesion or injury (Wu et al., 2014).
Microbiota and Therapy in AD
In one study the effects of probiotics on cognitive and metabolic function were investigated among patients with AD (Akbari et al., 2016). Compared to the control group, the study group taking a supplement of probiotics showed statistically significant improvements in their scores on the Minimental State Examination (MMSE): from 8.7 to 10.6 points (Akbari et al., 2016).
Taking a different approach, one preclinical study working with AD transgenic mice explored the properties of a probiotic mixture. The investigation demonstrated that probiotics noticeably reduced oxidative stress in the brains of AD transgenic mice (Bonfili et al., 2018).
However, other authors have concluded that for patients in the advanced stages of AD, taking probiotic supplements does not influence cognitive function or other biochemical factors (Agahi et al., 2018). This is despite the fact that previous work by the same authors using a different probiotic supplement showed that it had a favorable effect on cognition and other biochemical markers. In this way, not only are probiotic make-up and dose important but also the severity of disease and the time over which supplements are administered (Agahi et al., 2018).
In other work, it has been shown that antibiotics also induce changes in the gastrointestinal microbiota (Minter et al., 2016). It has been observed, in an AD mouse model, that long-term treatment with a combination regime of broad-spectrum antibiotics alters the composition and diversity of the intestinal microbiota and reduces the deposition of beta-amyloid plaques (Minter et al., 2016).
Finally, one investigation using adult rats inoculated with LPS showed that treatment with quercetin significantly reversed the synaptic loss induced by LPS in the cerebral cortex and the hippocampus, and improved the rats' performance in memory tasks (Khan et al., 2018).
Microbiota and Diet in AD
After a revision of multiple studies, it was discovered that the mechanisms that influence the onset of senile dementia and AD are associated with lowered levels of antioxidants and Omega-3 polyunsaturated fatty acids in the diet (Dohrmann et al., 2019). Consumption of Omega-3 fatty acids has a prophylactic effect against the neurotoxicity produced by AD, improves memory and learning, and increases neuronal protection. The longevity and high quality of life experienced by the Japanese is attributed to their diet. Likewise, the Mediterranean diet is recognized for its preventative benefits against certain chronic diseases and a reduction in the incidence of AD. These two dietary patterns ensure an intake of fatty acids and antioxidants at the same time as minimizing the intake of saturated fats from red meat. In contrast, the Argentine diet is characterized by a high consumption of processed and red meat, manufactured baked goods, and sugary drinks with a low intake of fish, fruits, and vegetables, all of which contribute to a higher risk of cognitive deterioration and AD (Dohrmann et al., 2019).
Dietary patterns containing a high level of fats tend to result in increased intestinal permeability and LPS absorption which, as a consequence, produce endotoxemia, systematic inflammation, and disease. By comparison, calorific restriction promotes health by optimizing the composition of the host microbiota by increasing the number of bacteria with positive health benefits, such as Lactobacillus, while reducing the number of bacteria malignant to the host (Mancuso and Santangelo, 2017).
One study looked at the effects of the Mediterranean diet on the microbiota (Fernández-Navarro et al., 2016). Findings showed that this diet is directly associated with a range of bacteria, such as Bacteroidetes, the Prevotellaceae family of bacteria and the Prevotella genus, and inversely related to the presence of bacteria of the Firmicutes phylum and Ruminococcus genus. Subjects who adhered most strongly to the Mediterranean diet had a higher proportion of Bacteroidetes, suggesting that this could be related to the greater consumption of carbohydrates, fiber, and vegetable proteins characteristic of this type of diet (Fernández-Navarro et al., 2016).
Thus, diet has been identified as a controllable environmental factor with a demonstrable influence on microbiota composition. One study completed with elders demonstrated that diet is associated with the microbiota to the degree that a healthy, varied diet promotes a more diverse gut microbiota (Claesson et al., 2012). Furthermore, evidence was uncovered for a connection between the intestinal microbiota and inflammation in elderly people (Claesson et al., 2012).
Prion Theory and AD
The full structure of PrPSc is not yet fully understood, however, it appears to be similar to that of amyloids which, like PrPSc, are a family of filament-like structures with a tendency to form protein clusters (Aguzzi, 2014). Beta-amyloid peptide, hyperphosphorylated protein Tau and PrPSc have a tertiary structure rich in beta sheets, which promotes the self-assembly of monomers in small oligomeric species that have neurotoxic and fibrillar assemblages (Sarnataro, 2018).
One hypothesis, for which increasingly stronger evidence is being gathered, is that the deposits of beta-amyloids found in AD patients disperse progressively throughout the brain, suggesting a propagation mechanism similar to that of prions. In one study, transgenic mice were inoculated with brain homogenates containing beta-amyloid clusters which resulted in increased beta-amyloid plaque formation in the brains of test subjects (Stöhr et al., 2012). This led the authors to conclude that beta-amyloid clusters are indeed able to self-propagate and for this reason may be considered as prions (Stöhr et al., 2012).
The authors of a work indicated that there are multiple investigations that conclude that both beta-amyloid peptide and tau protein can be aggregated and disseminated to the brain by a mechanism similar to the prion (Sarnataro, 2018).
In another study, the objective was to analyze the interaction between the mis-folding processes in proteins implicated in AD, and prion diseases (Morales et al., 2010). When AD transgenic mice with amyloid plaques were inoculated with prions, the symptoms of prion disease were observed to emerge rapidly. In addition, the deposition of amyloid plaques increased significantly in mice infected with prions in comparison with the non-inoculated control group. The authors suggest that there is a strong interaction between AD and prionic pathologies, indicating that the process of mis-folding in the case of one protein can be a risk factor for the appearance of mis-folding in other proteins (Morales et al., 2010).
In 2009, a study was presented concerning the analysis of results from an autopsy completed on a patient with sporadic CJD, that is, without any genetic component (Haraguchi et al., 2009). An anatomopathological examination of brain tissue post-mortem showed neuronal loss, astrocytosis, and characteristic patterns of spongiosis disease appearing in patches throughout the cerebral cortex and lenticular nucleus. Deposits of prion proteins were found in the cerebral cortex. Lewy bodies were also discovered in the cerebral cortex and the substantia nigra, and senile plaques, compatible with AD, were observed in the neocortex. The authors concluded that this was an unusual case in that the probability of CJD appearing in conjunction with Lewy body dementia and AD is extremely low (Haraguchi et al., 2009).
However, a year later some of the same authors of the study outlined above published a second article in which they analyzed the results of another autopsy on a patient suffering from a form of CJD with a codon mutation on the prion protein (Yoshida et al., 2010). The anatomopathological brain post-mortem revealed severe spongiosis, neuronal loss, and astrocytic gliosis in the cerebral cortex. Furthermore, senile plaques and neurofibrillary tangles were seen in areas of the neocortex. The conclusions of this study were that the relationship between the deposition of prion proteins and the co-presentation of AD in this case was significant. The authors suggested that beta-amyloid proteins can act as a promoting factor for the deposition of prion proteins (Yoshida et al., 2010).
In a recent study, in which Prusiner himself collaborated, anatomopathological analysis of a group of subjects was undertaken to assess the levels of two proteins similar to prions: beta-amyloid and pathological tau-proteins (Aoyagi et al., 2019). It was shown that the amount of pathological tau-protein present was inversely related to patient longevity. The authors interpreted this correlation as an indication that a high level of “prion-like” tau leads to the most severe forms of AD and leads to a fatal outcome much earlier than in patients where the activity of “prion-like” tau is much lower (Aoyagi et al., 2019).
In 2015, a group of researchers published an article based on the study of the autopsies of eight individuals with iatrogenic CJD (iCJD) (Jaunmuktane et al., 2015). Subjects ranged in age from 36 to 51 years and had all been treated with cadaveric pituitary human growth hormone. Surprisingly, the brains of these individuals with iCJD contained beta-amyloid plaques in the gray matter and in the blood vessels. The deposition of beta-amyloid observed in the gray matter is typical of that found in AD, and that found in the blood vessels is characteristic of cerebral angiopathy and is not generally related to the prion activity seen in CJD (Jaunmuktane et al., 2015).
None of the patients had pathological mutations, such as apolipoprotein E-4 (APOE-4) or other hereditary alleles associated with a high risk of developing early onset AD. The authors hypothesized that the significant parenchymal and vascular deposits of beta-amyloid seen in the four younger patients with iCJD compared with other patients suffering with prion disease and control subjects from the general population suggests iatrogenic transmission of the beta-amyloid pathology in addition to the CJD agent is a result of the growth hormone treatment they received. This shows that healthy people exposed in this way are potentially at risk of iatrogenic AD and amyloid cerebral angiopathy (Vogt et al., 2017). This evidence is, nevertheless, only circumstantial and causality could not be concluded. For this reason, a further article was published in 2018 in which the authors demonstrated that batches of human growth hormone contained particles of beta-amyloid, which would be consistent with the theory of iatrogenic, human to human, transmission of beta-amyloid pathology. Thus, there is growing evidence that, at least under highly controlled laboratory conditions, beta-amyloid clusters can be transmitted in a manner similar to that seen with prions (Ashe et al., 2013).
Despite the diversity of symptoms, it has been observed that the neuropathology of CJD shares certain features in common with AD, such as the neuronal damage, mitochondrial anomalies, and oxidative damage. Both diseases cause inflammatory changes that take place due to generalized microglial proliferation in the brain. The principal difference seen is that sporadic CJD causes death within a few months, whereas AD is a disease that, in the majority of cases, has a prognosis of ~10 years life-expectancy (Bastian, 2017).
The authors of one study looked at the converting enzyme TNF-α (TACE), known principally for its role in mediating the elimination of TNF-α receptors (Pietri et al., 2013). These researchers observed that this enzyme was less commonly found in neurones infected with pathological prions than in the neurones of people with AD due to increased activity of the enzyme PDK1 in these neurones. The purpose of the enzyme PDK1 is to induce phosphorylation and caveolin-1 mediated endocytosis of TACE. Therefore, it is suggested that pharmacologic inhibition of PDK1 to relocate TACE, thus restoring its neuroprotective function, could be useful in both diseases (Pietri et al., 2013).
Finally, it should be mentioned that many neurodegenerative diseases caused by protein plaques, such as AD, Parkinson's disease, and TSEs, are generally caused by genetic mutations or are sporadic in nature. However, the possible horizontal transmission of these diseases could pose a distinct threat to public health. In this case, the gut would undoubtedly play an important role in propagating the prion proteins responsible for TSEs and would also have a significant part in any hypothetical transmissibility of AD given how similar these pathologies appear to be (Da et al., 2011).
Recommendations for the Future
As future recommendations, we see interesting the implementation of diets that are adapted to AD. In these diets it would be remarkable if there were foods such as vegetables, fruit, whole grains, fish, nuts and dairy products with low fat content and a low percentage of candy, fried potatoes, processed meat, high saturated fat and butter.
We believe it would be interesting to look for a relationship between the proven increase in the prevalence of AD due to dietary changes with the appearance or increase in “prion-like” forms of beta-amyloids. This area is one that needs to be investigated further because there remain many unanswered questions and it could bring to bear significant findings that would contribute to our knowledge of the etiopathogenesis of this disease.
Another recommendation is to undertake a more in-depth evaluation of the therapeutic benefits to AD of controlled microbiota modification, either through fecal transplants, antibiotics, pro- and pre-biotic supplements, or diets specially designed with this pathology in mind.
Conclusions
The main conclusion of our work is that, the etiopathogenesis of AD has been associated with dietary factors, since an excessive intake of saturated fats or a deficiency of vitamin E, among others, influence the disease. These dietary factors can promote or prevent the degeneration of nerve cells. Thus, diet is a relevant factor in cognitive functioning in general and in AD in particular, being able to delay or reduce the patient's symptoms.
The microbiota of patients with AD has a characteristic composition and this is linked to the formation of beta-amyloid peptides, increased systematic proinflammatory activity, and subsequent mental decline. Furthermore, dysbiosis of the microbiota results in changes in GABA levels which contribute to functional deficit in the brains of patients with AD. Diets low in Omega-3 polyunsaturated fatty acids and antioxidants provide lower resistance to neurotoxicity, and a high consumption of sugars and saturated facts provokes systematic inflammation that affects the CNS due to the changes they produce in microbiota composition in patients with AD. Changes in microbiota composition in the gut as a result of different dietary habits is probably one of the environmental factors that impacts the development of AD.
Furthermore, a key feature of AD is the presence of beta-amyloid clusters in the brain that form as a result of self-propagating, abnormally folded, beta-amyloid proteins. These mis-folded proteins are pathological in nature and are remarkably similar to prions, having a molecular propagation mechanism that is almost identical. Although spontaneous mutation is the most widely accepted hypothesis for the appearance of AD, the prion theory should now be considered as a possible cause of this disease.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
Author Contributions
LS-V and LB-C: conception and design. LS-V, LB-C, IC-V, and JS-C: data acquisition. JAF-F and NF-M: analysis and interpretation. LS-V, LB-C, and IC-V: writing of the article. LS-V, JS-C, and MNF-M: review of the article. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., and Uberti, D. (2017). Nutrition and AGE-ing : focusing on Alzheimer' s disease. Oxid. Med. Cell. Longev. 2017:1–10. doi: 10.1155/2017/7039816
Abbott, A. (2016). The red-hot debate about transmissible Alzheimer's. Nature 531, 294–297. doi: 10.1038/531294a
Agahi, A., Hamidi, G. A., Daneshvar, R., and Hamdieh, M. (2018). Does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front. Neurol. 9:662. doi: 10.3389/fneur.2018.00662
Akbari, E., Asemi, Z., Kakhaki, R. D., and Bahmani, F. (2016). Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease : a randomized, double-blind and controlled trial. Front. Aging Neurosci. 8:256. doi: 10.3389/fnagi.2016.00256
Amato, A. D., Di, L., Mannelli, C., Lucarini, E., Man, A. L., Gall, G., et al. (2020). Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission- related proteins in young recipients. Microbiome 8, 1–19. doi: 10.1186/s40168-020-00914-w
Anastasiou, C. A., Yannakoulia, M., Kosmidis, M. H., Dardiotis, E., Hadjigeorgiou, G. M., Sakka, P., et al. (2017). Mediterranean diet and cognitive health: initial results from the Hellenic longitudinal investigation of ageing and diet. PLoS ONE 12:e0182048. doi: 10.1371/journal.pone.0182048
Aoyagi, A., Condello, C., Stöhr, J., Yue, W., Rivera, B. M., Lee, J. C., et al. (2019). Ab plaques and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. Sci. Transl. Med. 11, 1–14. doi: 10.1126/scitranslmed.aat8462
Ashe, K. H., Aguzzi, A., Ashe, K. H., and Aguzzi, A. (2013). Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 7, 55–59. doi: 10.4161/pri.23061
Association, A. (2018). 2018 Alzheimer's disease facts and figures. Alzheimer's Dement. 14, 367–429. doi: 10.1016/j.jalz.2018.02.001
Barnard, N. D., Bush, A. I., Ceccarelli, A., Cooper, J., de Jager, C. A., Erickson, K. I., et al. (2014). Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiol. Aging 35, S74–S78. doi: 10.1016/j.neurobiolaging.2014.03.033
Bastian, F. O. (2017). Combined Creutzfeldt-Jakob/Alzheimer's disease cases are important in search for microbes in Alzheimer's disease. Alzheimer's Dis. 56, 867–873. doi: 10.3233/JAD-160999
Bhardwaj, D., Mitra, C., Narasimhulu, C. A., Riad, A., Doomra, M., and Parthasarathy, S. (2017). Alzheimer's disease—current status and future directions. J. Med. Food 20, 1–11. doi: 10.1089/jmf.2017.0093
Bhattacharjee, S., and Lukiw, W. J. (2013). Alzheimer's disease and the microbiome. Front. Cell. Neurosci. 7:153. doi: 10.3389/fncel.2013.00153
Bonfili, L., Cecarini, V., Cuccioloni, M., Angeletti, M., Berardi, S., Scarpona, S., et al. (2018). SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol. Neurobiol. 55, 7987–8000. doi: 10.1007/s12035-018-0973-4
Brink Van Den, A. C., Brouwer-Brolsma, E. M., Berendsen, A. A. M., and Van De Rest, O. (2019). The mediterranean, dietary approaches to stop hypertension (DASH), and Mediterranean-DASH intervention for neurodegenerative delay (MIND) diets are associated with less cognitive decline and a lower risk of Alzheimer' s disease—a review. Am. Soc. Nutr. 10, 1–26.
Cardoso, B. R., Cominetti, C., and Cozzolino, S. M. F. (2013). Importance and management of micronutrient deficiencies in patients with Alzheimer's disease. Clin. Interv. Aging 8, 531–542. doi: 10.2147/CIA.S27983
Cattaneo, A., Cattane, N., Galluzzi, S., Lopizzo, N., Festari, C., Ferrari, C., et al. (2017). Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 47, 60–68. doi: 10.1016/j.neurobiolaging.2016.08.019
Claesson, M. J., Jeffery, I. B., Conde, S., and Power, S. E. (2012). Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178–184. doi: 10.1038/nature11319
Cox, L. M., and Weiner, H. L. (2018). Microbiota signaling pathways that influence neurologic disease. Am. Soc. Exp. Neurother. 15, 135–145. doi: 10.1007/s13311-017-0598-8
Da, B., Dias, C., Jovanovic, K., and Weiss, S. F. T. (2011). Alimentary prion infections. Prion 5, 6–9. doi: 10.4161/pri.5.1.14283
D'Argenio, V., and Sarnataro, D. (2019). Microbiome influence in the pathogenesis of prion and alzheimer's diseases. Int. J. Mol. Sci. 20, 1–16. doi: 10.3390/ijms20194704
Dohrmann, D. D., Putnik, P., Bursa,ć, D., Simal-gandara, J., Lorenzo, J. M., and Francisco, J. (2019). Japanese, Mediterranean and Argentinean diets and their potential roles in neurodegenerative diseases. Food Res. Int. 120, 464–477. doi: 10.1016/j.foodres.2018.10.090
Dominguez, L. J., and Barbagallo, M. (2016). Dietary approaches and supplements in the prevention of cognitive decline and Alzheimer's disease. Curr. Pharm. Des. 22, 1–13. doi: 10.2174/1381612822666151204000733
Europe, A. (2017). Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. Neurology. 32, 523–532. doi: 10.1016/j.nrleng.2016.02.009
Fern, P., and Ruiz-Gabarre, D. (2019). Modulating effect of diet on Alzheimer's disease. Diseases 7, 1–32. doi: 10.3390/diseases7010012
Fernández-Navarro, T., Sánchez, B., and Margolles, A. (2016). Function Mediterranean diet and faecal microbiota: a transversal study. R. Soc. Chem. 7, 2347–2356. doi: 10.1039/C6FO00105J
Gardener, S. L., and Rainey-Smith, S. R. (2018). The role of nutrition in cognitive function and brain ageing in the elderly. Curr. Nutr. Rep. 7, 139–149. doi: 10.1007/s13668-018-0229-y
Giau, V., Van W.u, S. Y., Jamerlan, A., An, S. S. A., Kim, S., and Hulme, J. (2018). Gut microbiota and their neuroinflammatory implications in Alzheimer's disease. Nutrients 10, 1–18. doi: 10.3390/nu10111765
Grant, W. B., and Grant, W. B. (2016). Using multicountry ecological and observational studies to determine dietary risk factors for Alzheimer' s disease. J. Am. Coll. Nutr. 35, 476–489. doi: 10.1080/07315724.2016.1161566
Guarnieri, G., Sarchielli, E., Comeglio, P., Herrera-puerta, E., Piaceri, I., Nacmias, B., et al. (2020). Tumor necrosis factor α influences phenotypic plasticity and promotes epigenetic changes in human basal forebrain cholinergic neuroblasts. Int. J. Mol. Sci. 21, 1–25. doi: 10.3390/ijms21176128
Guarnieri, G., Sarchielli, E., and Vannelli, G. B. M. A. (2018). Cell-based therapy in Alzheimer' s disease : can human fetal cholinergic neurons “untangle the skein”? Neural Regen. Res. 13, 2105–2107. doi: 10.4103/1673-5374.241459
Harach, T., Marungru, N., Duthilleul, N., Cheatham, V., Coy, K. D. M., and Frisoni, G. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep. 7, 1–13. doi: 10.1038/srep41802
Haraguchi, T., Terada, S., Ishizu, H., Sakai, K., Tanabe, Y., Nagai, T., et al. (2009). Coexistence of Creutzfeldt-Jakob disease, Lewy body disease, and Alzheimer' s disease pathology: an autopsy case showing typical clinical features of Creutzfeldt-Jakob disease. Neuropathology 29, 454–459. doi: 10.1111/j.1440-1789.2008.00964.x
Heiss, C. N., and Olofsson, L. E. (2018). The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. J. Neuroendocrinol. 31:e12684. doi: 10.1111/jne.12684
Hu, X., Wang, T., and Jin, F. (2016). Alzheimer's disease and gut microbiota. Sci. China Life Sci. 59, 1006–1023. doi: 10.1007/s11427-016-5083-9
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., et al. (2015). Evidence for human transmission of amyloid-b pathology and cerebral amyloid angiopathy. Nature 525, 247–250. doi: 10.1038/nature15369
Joseph, J., Cole, G., Head, E., and Ingram, D. (2009). Nutrition, brain aging, and neurodegeneration. J. Neurosci. 29, 12795–12801. doi: 10.1523/JNEUROSCI.3520-09.2009
Khan, A., Ali, T., Rehman, S. U., Khan, M. S., Alam, S. I., Ikram, M., et al. (2018). Neuroprotective effect of quercetin against the detrimental effects of LPS in the adult mouse brain. Front. Pharmacol. 9:1383. doi: 10.3389/fphar.2018.01383
Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D., and Gostner, J. M. (2018). Probiotic supplementation in patients with Alzheimer's dementia—an explorative intervention study. Curr. Alzheimer Res. 15, 1106–1113. doi: 10.2174/1389200219666180813144834
Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., and Zheng, H. (2016). Implications of GABAergic neurotransmission in Alzheimer's disease. Front. Aging Neurosci. 8:31. doi: 10.3389/fnagi.2016.00031
Lukiw, W. J. (2016). Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer's disease. Front. Microbiol. 7:1544. doi: 10.3389/fmicb.2016.01544
Mancuso, C., and Santangelo, R. (2017). Alzheimer's disease and gut microbiota modifications: the long way between preclinical studies and clinical evidence. Pharmacol. Res. 129, 329–336. doi: 10.1016/j.phrs.2017.12.009
Minter, M. R., Zhang, C., Leone, V., Ringus, D. L., Zhang, X., Chang, E. B., et al. (2016). Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci. Rep. 6, 1–12. doi: 10.1038/srep30028
Moore, K., Hughes, C. F., Ward, M., Hoey, L., and Mcnulty, H. (2018). Diet, nutrition and the ageing brain: current evidence and new directions. Proc. Nutr. Soc. 77, 152–163. doi: 10.1017/S0029665117004177
Morales, R., Estrada, L. D., Diaz-espinoza, R., Morales-scheihing, D., Jara, M. C., Castilla, J., et al. (2010). Molecular cross talk between misfolded proteins in animal models of Alzheimer' s and prion diseases. J. Neurosci. 30, 4528–4535. doi: 10.1523/JNEUROSCI.5924-09.2010
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., and Aggarwal, N. T. (2016). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's Dement. 11, 1007–1014. doi: 10.1016/j.jalz.2014.11.009
Mosconi, L., and McHugh, P. F. (2015). Let food be thy medicine: diet, nutrition, and biomarkers' risk of Alzheimer's disease. Curr. Nutr. Rep. 4, 126–135. doi: 10.1007/s13668-014-0111-5
Noh, H., Jeon, J., and Seo, H. (2014). Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochem. Int. 69, 35–40. doi: 10.1016/j.neuint.2014.02.008
Pendyala, S., Walker, J. M., and Holt, P. R. (2012). A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142, 1100–1101.e2. doi: 10.1053/j.gastro.2012.01.034
Perl, D. P. (2010). Neuropathology of Alzheimer' s disease. Mt. Sinai J. Med. 77, 32–42. doi: 10.1002/msj.20157
Pietri, M., Dakowski, C., Hannaoui, S., Alleaume-butaux, A., Hernandez-rapp, J., Ragagnin, A., et al. (2013). PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases. Nat. Med. 19, 1124–1131. doi: 10.1038/nm.3302
Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Thomas, J., Pamies, D., et al. (2016). Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget 7:38999. doi: 10.18632/oncotarget.9175
Purro, S. A., Farrow, M. A., Linehan, J., Nazari, T., Thomas, D. X., Chen, Z., et al. (2018). Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone. Nature 564, 415–419. doi: 10.1038/s41586-018-0790-y
Rai, S. N., Singh, C., Singh, A., Singh, M. P., and Singh, B. K. (2020). Mitochondrial dysfunction: a potential therapeutic target to treat Alzheimer' s disease. Mol. Neurobiol. 57, 3075–3088. doi: 10.1007/s12035-020-01945-y
Ravi, S. K., Narasingappa, R. B., and Vincent, B. (2018). Neuro-nutrients as anti-Alzheimer's disease agents : a critical review. Crit. Rev. Food Sci. Nutr. 59, 2999–3018. doi: 10.1080/10408398.2018.1481012
Rosa, F., La C.lerici, M., Ratto, D., Occhinegro, A., Licito, A., Romeo, M., et al. (2018). The Gut–Brain axis in Alzheimer's disease and Omega-3. A critical overview of clinical trials. Nutrients 10, 1–17. doi: 10.3390/nu10091267
Sampson, T. R., Mazmanian, S. K., and Engineering, B. (2016). Control of brain development, function, and behavior by the microbiome timothy. Cell Host Microbe 17, 565–576. doi: 10.1016/j.chom.2015.04.011
Sarchielli, E., Guarnieri, G., Idrizaj, E., Squecco, R., Mello, T., Comeglio, P., et al. (2020). The G protein-coupled oestrogen receptor, GPER1, mediates direct anti-inflammatory effects of oestrogens in human cholinergic neurones from the nucleus basalis of Meynert. J. Neuroendocrinol. 32, 1–13. doi: 10.1111/jne.12837
Sarnataro, D. (2018). Attempt to untangle the prion-like misfolding mechanism for neurodegenerative diseases. Int. J. Mol. Sci. 19, 1–17. doi: 10.3390/ijms19103081
Singh, R. K., Chang, H. W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., et al. (2017). Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 15, 1–17. doi: 10.1186/s12967-017-1175-y
Stöhr, J., Watts, J. C., Mensinger, Z. L., Oehler, A., Grillo, S. K., and Dearmond, S. J. (2012). Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. PNAS 109, 11025–11030. doi: 10.1073/pnas.1206555109
Toni, M., Massimino, M. L., Mario, A., De Angiulli, E., and Spisni, E. (2017). Metal dyshomeostasis and their pathological role in prion and prion-like diseases: the basis for a nutritional approach. Front. Neurosci. 11:3. doi: 10.3389/fnins.2017.00003
Venturini, L., Perna, S., Sardi, F., Faliva, M. A., Cavagna, P., Bernardinelli, L., et al. (2014). Alzheimer's disease: from genes to nutrition. Eur. J. Inflamm. 12, 405–414. doi: 10.1177/1721727X1401200301
Vieira, L., Liliana, M., Andrade, F., Ramos, D. O., and Chiarello, P. G. (2014). Nutritional status according to the stages of Alzheimer's disease. Aging Clin. Exp. Res. 27, 507–513. doi: 10.1007/s40520-014-0302-3
Vogt, N. M., Kerby, R. L., Dill-mcfarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., et al. (2017). Gut microbiome alterations in Alzheimer's disease. Sci. Rep. 7, 1–11. doi: 10.1038/s41598-017-13601-y
Walker, L. C., and Jucker, M. (2015). Neurodegenerative diseases : expanding the prion concept. Annu. Rev. Neurosci. 38, 87–103. doi: 10.1146/annurev-neuro-071714-033828
Wu, Z., Guo, Z., Gearing, M., and Chen, G. (2014). Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nat. Commun. 5, 1–12. doi: 10.1038/ncomms5159
Yoshida, H., Terada, S., Ishizu, H., Ikeda, K., Hayabara, T., Ikeda, K., et al. (2010). An autopsy case of Creutzfeldt-Jakob disease with a V180I mutation of the PrP gene and Alzheimer-type pathology. Neuropathology 30, 159–164. doi: 10.1111/j.1440-1789.2009.01048.x
Zhan, X., Stamova, B., and Sharp, F. R. (2018). Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer' s disease brain : a review. Front. Neurosci. 10:42. doi: 10.3389/fnagi.2018.00042
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., et al. (2019). Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci. Rep. 9, 1–12. doi: 10.1038/s41598-019-42286-8
Keywords: nutrition, Alzheimer's disease, neuroinflammation, microbiome, prion
Citation: Bello-Corral L, Sánchez-Valdeón L, Casado-Verdejo I, Seco-Calvo J, Antonio Fernández-Fernández J and Nélida Fernández-Martínez M (2021) The Influence of Nutrition in Alzheimer's Disease: Neuroinflammation and the Microbiome vs. Transmissible Prion. Front. Neurosci. 15:677777. doi: 10.3389/fnins.2021.677777
Received: 22 March 2021; Accepted: 28 July 2021;
Published: 20 August 2021.
Edited by:
Sebastian Cerdan, Autonomous University of Madrid, SpainReviewed by:
David Brooks, Imperial College London, United KingdomDaniela Sarnataro, University of Naples “Federico II”, Italy
Copyright © 2021 Bello-Corral, Sánchez-Valdeón, Casado-Verdejo, Seco-Calvo, Antonio Fernández-Fernández and Nélida Fernández-Martínez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Leticia Sánchez-Valdeón, bHNhbnYmI3gwMDA0MDt1bmlsZW9uLmVz